New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;IQNT;GRMN;JCP;JNJ;KRC;NKTR;STRA;VRTX;VNO;BMY;PBR;HES From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
October 17, 2014
16:55 EDTJCP, JNJStocks end volatile week lower amid oil price plunge
Subscribe for More Information
16:01 EDTPBROptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
10:37 EDTJNJOptions with decreasing implied volatility: ATLS JNJ XLNX JNK HYG
Subscribe for More Information
10:27 EDTVRTXVertex FDA panel expected to be positive at Piper Jaffray
Subscribe for More Information
10:26 EDTVRTXFDA panel asked to consider benefit of Vertex drug in younger CF patients
Subscribe for More Information
10:00 EDTGRMNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:57 EDTJNJPharmacyclics price target raised to $188 from $185 at Roth Capital
Subscribe for More Information
08:51 EDTJNJPharmacyclics announces European approval for Imbruvica
Subscribe for More Information
08:19 EDTGRMNGarmin initiated with a Neutral at Credit Suisse
Subscribe for More Information
08:02 EDTJNJCovidien granted preliminary injunction against Ethicon's Harmonic ACE+7
Subscribe for More Information
October 16, 2014
16:01 EDTPBROptions Update; October 16, 2014
Subscribe for More Information
14:58 EDTCATArmy poised to order more Stryker vehicles, Defense News says
Subscribe for More Information
14:47 EDTJNJRoche in pact with Pharmacyclics to evaluate Imbruvica, Gazyva combo
Subscribe for More Information
13:01 EDTPBRPetrobras Comperj refinery is 60% over budget, Bloomberg reports
Petrobras's Comperj refinery is 60% over budget, Bloomberg reports, citing the tribunal overseeing state spending. The Comperj refinery is scheduled to open in 2016 and will cost Petrobras $21.6B to complete, Bloomberg added. Reference Link
11:17 EDTCATTitan downturn warning seen as negative for Deere, AGCO
Subscribe for More Information
10:01 EDTBMYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:41 EDTCATTitan outlook negative for AGCO, Deere, says Wells Fargo
Subscribe for More Information
09:39 EDTPBRActive equity options trading on open
Subscribe for More Information
08:42 EDTBMYBristol-Myers upgraded at BMO Capital
Subscribe for More Information
06:16 EDTBMYBristol-Myers upgraded to Outperform from Market Perform at BMO Capital
October 15, 2014
16:00 EDTPBROptions Update; October 15, 2014
Subscribe for More Information
09:57 EDTJNJ, BMYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:38 EDTJNJActive equity options trading on open
Subscribe for More Information
09:15 EDTJNJJ&J comments positive for Anika Therapeutics, says Summer Street
Subscribe for More Information
07:44 EDTHESHess volatility at five-year highs as oil trends below $81
Subscribe for More Information
07:37 EDTJNJJohnson & Johnson pullback a buying opportunity, says Leerink
Subscribe for More Information
07:34 EDTJNJJohnson & Johnson reported strong Q3 results, says Argus
Subscribe for More Information
07:14 EDTJNJJohnson & Johnson price target lowered to $110-$111 from $119-$120 at Wells Fargo
Subscribe for More Information
07:07 EDTSTRAFor profit education positive catalysts outweigh negative, says Wells Fargo
Wells Fargo expects for-profit education stocks to benefit from improved hiring trends and a sale by Corinthian of its assets that, according t othe firm ,would set a valuation floor for the sector. The firm continues to believe that the final gainful employment rule will be neutral to positive for the group. Wells favors the option value on the long side for the sector. Publicly traded companies in the space include American Public Education (APEI), Apollo Education (APOL), Bridgepoint Education (BPI), Career Education (CECO), Corinthian Colleges (COCO), DeVry (DV), Grand Canyon (LOPE), ITT Educational (ESI) and Strayer (STRA).
October 14, 2014
16:22 EDTJNJOn The Fly: Closing Wrap
The Wall Street averages were mixed after three of the U.S.'s largest banks reported on their quarterly results and Germany slashed its economic forecasts for this year and next. Following the mostly solid earnings reports from the banks and Dow member Johnson & Johnson (JNJ) investors appeared to breathe a sigh of relief and sent the averages higher in early trading. With oil prices falling almost 5% and settling at a recent low, the averages pared their gains and struggled in positive ground. Another late day slide ended with the averages mixed, as the Nasdaq led and the Dow lagged. ECONOMIC EVENTS: In the U.S., the International Energy Agency said in its monthly oil market report that world oil demand growth would be weaker than previously expected. Afterward, WTI crude oil futures fell 4.6% at $81.84, marking their biggest percentage drop since late 2012 and the lowest settlement for the benchmark in over two years. The National Federation of Independent Business' small business optimism index came in at 95.3, versus the consensus expectation for a 95.8 reading. In Europe, Germany's government cut its forecasts for gross domestic product growth to 1.2% in 2014 and 1.3% next year from its prior view of 1.8% growth this year and 2% in 2015. COMPANY NEWS: The first of America's big banks issued their quarterly reports, with JPMorgan's (JPM) headline earnings per share coming in below analysts’ consensus estimate, Wells Fargo (WFC) reporting in-line earnings and improved credit quality and Citigroup (C) posting better than expected adjusted third quarter profit. Citi, which also announced plans to pull back from retail banking in eleven countries and said it will disband a legacy Banamex unit after an investigation uncovered illegal conduct, saw its stock fare the best among the three, rising $1.57, or 3.15%, to $51.47... Another Dow member, Johnson & Johnson, reported better than expected profits and revenues and raised its FY14 EPS outlook, but its stock slid $2.11, or 2.13%, to $97.01. MAJOR MOVERS: Among the notable gainers was Domino's Pizza (DPZ), which rose $8.58, or 11.33%, to $84.30 after the pizza chain owner and franchisor reported better than expected third quarter earnings per share and revenue. Also higher was Skyworks (SWKS), which advanced $3.59, or 7.92%, to $48.91 after the supplier of chips to Apple (AAPL) raised its fourth quarter earnings per share outlook and revenue guidance. Among the noteworthy losers was Exactech (EXAC), which dropped $4.09, or 16.63%, to $20.50 after the company warned its Q3 income and revenue will likely miss its prior guidance. Also lower were shares of Gilead (GILD), which fell $4.26, or 4.2%, to $97.18 amid a number of developments. Competitor Johnson & Johnson said it would seek to make its own hepatitis C treatment accessible and "competitive," which some may have read as an indication of a potential price cut, and Ireland said it plans to close its "Irish Double" tax loophole, which currently benefits Gilead. INDEXES: The Dow slipped 5.88, or 0.04%, to 16,315.19, the Nasdaq rose 13.52, or 0.32%, to 4,227.17, and the S&P 500 added 2.96, or 0.16%, to 1,877.70.
16:00 EDTPBROptions Update; October 14, 2014
iPath S&P 500 VIX Short-Term Futures down 40c to 39.11. Option volume leaders: AAPL TSLA TWTR AMZN GILD C JNJ AA NFLX PBR according to Track Data.
13:59 EDTVRTXVertex mentioned cautiously at BofA/Merrill
12:41 EDTJNJGilead retreats following Johnson & Johnson comments on HCV drug
Shares of Gilead (GILD), which has developed a hepatitis C treatment, are retreating after Johnson & Johnson (JNJ) said it would seek to make its own hepatitis C treatment accessible and competitive. Some investors believe that Johnson & Johnson's comments suggest that it will cut the price of its hepatitis C drug. WHAT'S NEW: Johnson & Johnson said on its earnings conference call today that it was "committed" to its treatment for hepatitis C virus, or HCV. The company added that it intends to remain competitive in the space and would look to make its HCV treatment, Olysio, accessible. In a separate development today, The Wall Street Journal reported that Abbvie (ABBV), which also has an HCV treatment, may have to consider pricing its HCV drug more aggressively after Gilead received FDA approval for Harvoni, the first combination pill approved to treat chronic HCV genotype 1 infection. One analyst quoted by The Journal, Roger Longman, said that AbbVie should consider pricing its drug at $76,000 for a 12 week regimen, representing a 20% discount to Harvoni, which will be priced at $94,500 for a full 12 week regimen. ANALYST REACTION: In a note to investors earlier today, RBC Capital analyst Michael Yee wrote that the weakness in Gilead's stock today has created a buying opportunity. Johnson & Johnson probably can't reduce the price of its Olysio drug much, since it is often used in combination with Gilead's Sovaldi, which costs $84,000 for 12 weeks, RBC Capital analyst Michael Yee wrote in a note to investors today. The price of AbbVie's treatment is unlikely to be much below Sovaldi's price, the analyst stated. WHAT'S NOTABLE: Gilead, along with a number of other drug companies, may also be under pressure because Ireland is reportedly closing its "Irish Double" tax loophole. Gilead is one of the companies that currently benefits from the "Irish Double," but Yee says that closing the loophole should only have a "minimal" impact on Gilead. PRICE ACTION: In early afternoon trading, Gilead fell 3.3% to $98.10, AbbVie gained 1.7% to $54.53 and Johnson & Johnson lost 0.6% to $98.52.
12:33 EDTJNJZimmer, Stryker have postive read-through from J&J, says Wells Fargo
Subscribe for More Information
12:20 EDTJNJOn The Fly: Midday Wrap
Stocks on Wall Street were higher at midday after three of the nation's largest banks reported on their results in the most recent quarter of the year. The market began the session in positive territory but the move seemed tenuous and the averages were almost back in negative ground within a half hour of the opening bell. As the morning progressed and the bears were unable to gain control, the buyers emerged and pushed the Dow to a triple digit gain and the Nasdaq to an increase of nearly 1.5%. ECONOMIC EVENTS: In the U.S., the National Federation of Independent Business' small business optimism index came in at 95.3, versus the consensus expectation for a 95.8 reading. COMPANY NEWS: JPMorgan (JPM) swung to a third quarter profit, but its headline earnings per share fell below analysts’ consensus estimate. Of note, the company's press release on its results came out earlier than planned on Nasdaq's (NDAQ) Shareholder.com website, which the exchange operator attributed to an internal "human error." Wells Fargo (WFC) reported in-line earnings and stronger credit quality, but its stock slid 1.4% following the report. Citigroup (C) generated the most headlines, however, as it reported better than expected adjusted third quarter profit, announced plans to pull back from retail banking in eleven countries and said it will disband a legacy Banamex unit that provided personal security services after an investigation uncovered illegal conduct. Shares of Citi bucked the trend set by its two peers, rising 3% near noon... In addition to JPMorgan, Dow member Johnson & Johnson (JNJ) reported on its third quarter earnings. The drug and medical device giant reported better than expected profits and revenues and raised its FY14 EPS outlook, but the stock was fractionally lower near midday. MAJOR MOVERS: Among the notable gainers was Energy Transfer Equity (ETE), which gained 8.5% after the stock was among the energy industry names upgraded this morning at RW Baird. Also higher was Skyworks (SWKS), which rose 11% after the company preannounced stronger than expected results that its CEO attributed to the "broad-based strength" of its business. Among the noteworthy losers was EnerNOC (ENOC), which dropped 11% after JPMorgan downgraded the stock to Neutral citing risk to the company's Demand Response revenue at PJM given the challenge to FERC Rule 745. Also lower was Tyco (TYC), which fell nearly 4% after Barclays downgraded the stock citing valuation and coupled the ratings change with an upgrade of Eaton (ETN). INDEXES: Near midday, the Dow was up 133.38, or 0.82%, to 16,454.45, the Nasdaq was up 60.63, or 1.44%, to 4,274.29, and the S&P 500 was up 21.51, or 1.15%, to 1,896.25.
11:23 EDTJNJ, BMYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:11 EDTJNJJohnson & Johnson Ortho strength positive for Zimmer, says Piper Jaffray
Piper Jaffray said Johnson & Johnson's (JNJ) sequential Q3 strength in orthopedics, which included acceleration in both hips and knees, was surprising and a positive for Zimmer (ZMH). However, Piper expect sentiments on ortho names to remain muted until further into reporting season, noting that Stryker (SYK) is scheduled to report Thursday after the close. The firm has Neutral rating on Johnson & Johnson and Stryker and an Overweight rating on Zimmer.
10:51 EDTJNJGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:41 EDTJNJGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:05 EDTJNJAbbVie could cause Hep C price tipping point with aggressive pricing, WSJ says
Subscribe for More Information
09:14 EDTJNJJ&J sees FY14 pre-tax operating margin significantly improved vs. FY13
Subscribe for More Information
09:13 EDTJNJOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Johnson & Johnson (JNJ), up 1%... Dominos Pizza (DPZ), up 2.7%. ALSO HIGHER: Citigroup (C), up 2.5% following earnings report, announcement of plans to exit consumer businesses in 11 markets... MagneGas (MNGA), up 14% after signing Letter of Intent with Pioneer Recycling... Skyworks (SWKS), up 6% after raising its outlook for Q4. Shares of peers Avago (AVGO), NXP Semiconductors (NXPI) and RF Micro Devices (RFMD) are also moving higher in pre-market trading after Skyworks pointed to "broad-based strength" of its business in raising its outlook... Halcon Resources (HK), up 6% after upgraded at KLR Group... Quantum (QTM), up 8.8% after issuing Q2 earnings guidance. LOWER: Wells Fargo (WFC), down 1.4% after reporting in-line Q3 earnings... JPMorgan (JPM), down 1.8% after Q3 headline earnings miss... Las Vegas Sands (LVS), down 1% following downgrade at BofA Merrill Lynch.
08:58 EDTJNJJ&J sees FY14 operating sales on constant currency basis up 5.5%-6.5%
Subscribe for More Information
08:46 EDTJCPHome Depot announces resignation of Marvin Ellison as EVP - U.S. Stores
Subscribe for More Information
07:50 EDTJNJJohnson & Johnson: Alios BioPharma transaction expected to close in Q4 of 2014
Subscribe for More Information
07:50 EDTJNJJohnson & Johnson reports Q3 Worldwide Consumer sales down 0.6% to $3.6B
Subscribe for More Information
07:49 EDTJNJJohnson & Johnson raises FY14 EPS to $5.92-$5.97 from $5.85-$5.92
Subscribe for More Information
07:48 EDTJNJJohnson & Johnson reports Q3 domestic sales up 11.6% to $8.84B
Reports Q3 international sales down 0.3% to $9.63B. Worldwide, domestic and international operational sales growth, excluding the impact of this divestiture, was 8.4%; 14.8% and 3.1% respectively.
07:46 EDTJNJJohnson & Johnson reports Q3 adjusted EPS $1.50, consensus $1.44
Subscribe for More Information
07:15 EDTJCPJ.C. Penney new CEO may not have expertise in right areas, says Wells Fargo
Subscribe for More Information
October 13, 2014
16:28 EDTJCPOn The Fly: Closing Wrap
Stocks on Wall Street spent most of today's quiet session see-sawing across the flat-line before dropping sharply in the final hour of trading and closing at their lows. The market opened in negative territory but soon made a move to the upside and appeared ready to break the recent market slide that has seen the S&P lose about 5% of its value. Before the averages gained significant steam, they reversed again and moved back into negative ground. The averages moved in a fairly narrow range for most of the afternoon, before accelerating to the downside with conviction in the final hour of trading. ECONOMIC EVENTS: In the U.S., no economic data of note was reported and banks and bond markets were closed in observance of the Columbus Day holiday. In China, the nation's customs administration reported a trade surplus of about $31B for September. Exports in the month increased 15.3% from a year earlier, beating expectations and making for the biggest monthly increase since February 2013. Imports rose 7%, significantly outpacing the consensus projection for a 2% decline. COMPANY NEWS: The Wall Street Journal reported that CSX (CSX) was approached by a larger rival, Canadian Pacific (CP), about a possible merger. However, Credit Suisse analyst Allison Landry wrote in a note to investors that a merger between the two would not be able to occur, due to high regulatory hurdles. Still, CSX rose $1.76, or 5.88%, to $31.70 following the Journal's report, while Canadian Pacific fell $4.40, or 2.32%, to $184.97... Shares of Fiat Chrysler Automobiles (FCAU) made their debut on the New York Stock Exchange and opened at $9 per share. The stock of the newly merged company closed trading down about 1% at $8.92... J.C. Penney (JCP) selected Marvin Ellison, who is currently executive vice president of stores at Home Depot (HD), to become its next CEO. The stock, which was also downgraded to Sell from Neutral at UBS this morning, spent much of the trading day in positive ground but moved lower late in the session and closed down 3c, or 0.42%, at $7.09. MAJOR MOVERS: Among the notable gainers was Alnylam (ALNY), which advanced $13.83, or 18.98%, to $86.68 after the company announced data from study of its treatment for patients with familial amyloidotic polyneuropathy and Piper Jaffray raised its price target on the stock to $133 from $101 citing the trial results. Among the noteworthy losers was AutoNation (AN), which fell $4.11, or 8.01%, to $47.21 after another company in the same sector, Lithia Motors (LAD), lowered its profit outlook for the third and fourth quarter and issued a lower than expected earnings forecast for fiscal 2015. Shares of Lithia, meanwhile, plunged $16.85, or 20.84%, to $64.01. Also lower were shares of GoPro (GPRO), which fell $8.38, or 9.85%, to $76.67 after a French journalist reported that the son of racing legend Michael Schumacher attributed the severity of his father's brain injury following a skiing accident on the GoPro camera mounted to his helmet. INDEXES: The Dow fell 223.03, or 1.35%, to 16,321.07, the Nasdaq dropped 62.58, or 1.46%, to 4,213.66, and the S&P 500 declined 31.39, or 1.65%, to 1,874.74.
15:24 EDTJNJNotable companies reporting before tomorrow's open
Subscribe for More Information
14:24 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
14:15 EDTJNJEarnings Preview: Johnson & Johnson looks to new drugs to boost Q3 sales
Subscribe for More Information
14:08 EDTJNJJohnson & Johnson technical notes before earnings
Subscribe for More Information
12:16 EDTJCPOn The Fly: Midday Wrap
Stocks on Wall Street were slightly lower at midday amid light trading volume. Banks and bond markets are closed in observance of the Columbus Day holiday, though equity markets remain open. ECONOMIC EVENTS: In the U.S., no major economic data was reported. COMPANY NEWS: Shares of a number of freight train operators rose after The Wall Street Journal reported that one of the companies in the sector, CSX (CSX), was approached by a larger rival, Canadian Pacific (CP), about a possible merger. Following the Journal's report, CSX rose 10% and Canadian Pacific advanced 1%, while Norfolk Southern (NSC) and Kansas City Southern (KSU) both climbed about 3%... Chrysler returned to the U.S. stock market, as shares of Fiat Chrysler began trading on the New York Stock Exchange under the symbol "FCAU." MAJOR MOVERS: Among the notable gainers was J.C. Penney (JCP), which rose 3% after the company selected Marvin Ellison, who is currently executive vice president of stores at Home Depot (HD), to become its next CEO. Also higher were Atlas Energy (ATLS), which rose 20%, and Atlas Pipeline Partners (APL), which advanced 6%, after Targa Resources Partners (NGLS) and Targa Resources (TRGP) agreed to acquire Atlas Pipeline Partners for cash and stock valued at $38.66 per APL common unit and agreed to buy Atlas Energy following the company's spin-off of its non-midstream assets. Among the noteworthy losers was Aerohive Networks (HIVE), which plunged 30% after the company lowered its guidance for the third quarter, citing weaker-than-expected order volume near the quarter's end. Also lower were shares of GoPro (GPRO), which fell over 8% after a French journalist reported that the son of racing legend Michael Schumacher attributed the severity of his father's brain injury following a skiing accident on the GoPro camera mounted to his helmet. INDEXES: Near midday, the Dow was down 32.14, or 0.19%, to 16,511.96, the Nasdaq was down 7.97, or 0.19%, to 4,268.27, and the S&P 500 was down 6.85, or 0.36%, to 1,899.28.
12:05 EDTJCPJ.C. Penney risk/reward remains balanced, says RW Baird
Subscribe for More Information
10:12 EDTJCPHome Depot bench deep, Ellison departure not surprising, says RW Baird
RW Baird said it is not surprised to see Marvin Ellison leaving Home Depot (HD) since he was likely in the running for the CEO post that went to someone else, but the firm expects a smooth internal transition and noted that it views the company's management bench as deep. Baird, which maintains its Outperform rating on Home Depot, believes J.C. Penney (JCP) is getting a strong leader with extensive retail experience in hiring Ellison.
10:08 EDTJCPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Bankrate (RATE) downgraded to Equal Weight from Overweight at Stephens... CME Group (CME) downgraded to Market Perform from Outperform at Wells Fargo... Cliffs Natural (CLF) downgraded to Neutral from Overweight at JPMorgan... Dana Holding (DAN) downgraded to Sector Perform from Outperform at RBC Capital... Darden (DRI) downgraded to Neutral from Overweight at Piper Jaffray... Dover (DOV) downgraded to Neutral at RW Baird... DryShips (DRYS) downgraded to Underperform from Outperform at Imperial Capital... Infineon (IFNNY) downgraded to Neutral from Overweight at JPMorgan... J.C. Penney (JCP) downgraded to Sell from Neutral at UBS... Johnson Controls (JCI) downgraded to Outperform from Top Pick at RBC Capital... Juniper (JNPR) downgraded to Hold from Buy at Argus... Kennametal (KMT) downgraded to Market Perform from Outperform at Wells Fargo... Masco (MAS) downgraded to Equal Weight from Overweight at Barclays... New Gold (NGD) downgraded to Neutral from Overweight at JPMorgan... ON Semiconductor (ONNN) downgraded to Sector Perform from Outperform at Pacific Crest... PBF Energy (PBF) downgraded to Underweight from Equal Weight at Barclays... Parker-Hannifin (PH) downgraded to Market Perform from Outperform at Wells Fargo... STMicroelectronics (STM) downgraded to Neutral from Overweight at JPMorgan... Silicon Laboratories (SLAB) downgraded to Sector Perform at Pacific Crest... VOXX International (VOXX) downgraded to Market Perform from Outperform at Cowen.
10:08 EDTVRTXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
10:06 EDTJCPJ.C. Penney rises after selecting Home Depot executive as next CEO
Subscribe for More Information
09:39 EDTPBRActive equity options trading on open
Subscribe for More Information
09:23 EDTVRTXVertex price target raised to $131 from $119 at RW Baird
Subscribe for More Information
08:40 EDTJNJAlios BioPharma reports positive results for AL-8176 in Phase 2 study
Alios BioPharma presented results from a randomized, double-blind, placebo-controlled Phase 2 challenge study of its oral anti-RSV nucleoside analog AL-8176 this past weekend at the IDWeek 2014 Conference in Philadelphia, PA. The study was conducted in healthy adult volunteers who were infected intranasally with respiratory syncytial virus, or RSV. AL-8176 achieved its primary and secondary endpoints of reduction in viral load and improvement in symptom scores as compared to placebo. AL-8176 was well tolerated with no discontinuations of study drug and no clinically significant laboratory abnormalities. In successfully infected subjects, a rapid and marked reduction in RSV viral load was observed following treatment in all three AL-8176 treated dose groups as compared to placebo. In contrast, successfully infected placebo subjects exhibited a logarithmic increase in RSV RNA with a peak viral load at Day 3.5 following start of dosing with placebo. The mean time to non-detectability of RSV RNA was 1.3-2.3 days for the AL-8176 treatment groups compared to 7.2 days in the placebo group. At discharge, all subjects treated with AL-8176 were RSV RNA undetectable and remained RSV RNA undetectable upon follow-up on Days 16 and 28. The viral load reduction in infected subjects across all AL-8176 dosing regimens was associated with concomitant improvements in RSV symptom scores and reductions in mucus weight. On September 30, Johnson & Johnson announced a definitive agreement to acquire Alios.
08:38 EDTJCPJ.C. Penney names Marvin Ellison CEO-Designee
The board of J. C. Penney (JCP) announced the appointment of Marvin Ellison, currently executive vice president of stores at Home Depot (HD), as president and CEO-Designee, effective November 1. Ellison will also join the board. He will then succeed Myron E. Ullman, III as CEO of JCPenney on August 1, 2015. At that time, Ullman will become executive chairman of the board for a period of one year.
08:05 EDTBMY, JNJBristol-Myers, Pharmacyclics, Janssen announce clinical collaboration
Bristol-Myers Squibb Company (BMY), Pharmacyclics, Inc. (PCYC), and Janssen Research & Development, LLC (JNJ) announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor OPDIVO in combination with IMBRUVICA, an oral Bruton's tyrosine kinase inhibitor co-developed and co-marketed by Pharmacyclics and Janssen. The Phase 1/2 study will focus on evaluating the safety and anti-tumor activity of combining OPDIVO and IMBRUVICA as a potential treatment option for patients with non-Hodgkin lymphoma, including diffuse large B-cell lymphoma, follicular lymphoma and chronic lymphocytic leukemia. Bristol-Myers Squibb has proposed the name OPDIVO, which if approved by health authorities, will serve as the trademark for the investigational drug, nivolumab. OPDIVO is part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body’s own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Each agent has individually shown activity against hematologic malignancies in clinical trials; pre-clinical evidence suggests OPDIVO and IMBRUVICA may have the potential for additive treatment effects in patients with hematologic malignancies. The study will be conducted by Janssen. Additional details of the collaboration were not disclosed.
07:25 EDTJNJEuropean Association of Cardiothoracic Surgery to hold annual meeting
28th EACTS Annual Meeting is being held in Milan, Italy on October 11-15.
07:15 EDTJNJNational Association of Corporate Directors to hold a conference
Subscribe for More Information
07:13 EDTBMY, JNJBioFlorida to hold a conference
Subscribe for More Information
06:15 EDTJCPJ.C. Penney downgraded to Sell from Neutral at UBS
UBS downgraded its rating on J.C. Penney (JCP) shares to Sell saying the company's 2017 EBITDA target of $1.2B is overly optimistic as it assumes years of market share gains against strong competitors like Macy's (M) and Kohl's (KSS). UBS halved its price target for Penney shares to $5 from $10. The retailer's stock closed Friday down 52c to $7.12.
05:35 EDTVRTXVertex upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray upgraded Vertex Pharmaceuticals to Overweight citing likely approval of the company's Kalydeco plus lumacaftor combination next year. Piper expects Vertex's Cystic Fibrosis sales to grow to $3.1B in 2016 and raised its price target for shares to $125 from $87.50.
October 10, 2014
16:02 EDTPBRActionable Options for Friday, October, 10
Subscribe for More Information
12:11 EDTPBROptions with increasing implied volatility
Subscribe for More Information
10:05 EDTHESHess calls active on renewed takeover chatter
Hess October 84 and 85 calls area active on total call volume of 2,700 contracts (300 puts) on renewed takeover chatter. October call option implied volatility is at 37, November is at 32, December is at 30, January is at 27; compared to its 26-week average of 20 according to Track Data. Active call volume suggests traders taking positions for large price movement.
10:03 EDTBMYBristol-Myers receives orphan status for melanoma treatment
Subscribe for More Information
10:01 EDTJCPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:01 EDTJNJOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:55 EDTHESRumor: Hess Corp. moves up on renewed takeover chatter
Subscribe for More Information
09:38 EDTPBRActive equity options trading on open
Subscribe for More Information
08:24 EDTVRTXVertex price target raised to $117 from $109 at Maxim
Maxim raised its price target for Vertex shares to $117 after the company gave an update at the Cystic Fibrosis Conference. The form keeps a Buy rating on the stock.
08:19 EDTJNJ, BMYMedivir announces Janssen initiates enrolment in phase II IMPACT study
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson reports additional data from ATTAIN study
Subscribe for More Information
07:57 EDTJCPJ.C. Penney downgraded to Sell with $4 target at Maxim
Subscribe for More Information
07:10 EDTJCPJ.C. Penney downgraded to Sell from Hold at Maxim
Subscribe for More Information
07:07 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
Subscribe for More Information
06:27 EDTJNJJohnson & Johnson upgraded to Neutral from Underperform at Credit Suisse
October 9, 2014
16:00 EDTPBROptions Update; October 9, 2014
Subscribe for More Information
12:46 EDTSTRADoE policy changes a negative for select Education stocks, says Deutsche Bank
Subscribe for More Information
11:00 EDTPBROptions with increasing implied volatility
Options with increasing implied volatility: ARWR PBR EXXI PWE GST GLNG WTW AFSI ETE VALE
10:00 EDTJCPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:38 EDTPBRActive equity options trading on open
Subscribe for More Information
09:33 EDTVRTXVertex says VX-661 Phase 2 study fully enrolled
Subscribe for More Information
08:13 EDTJCPJ.C. Penney EBITDA guidance appears aggressive, sasy Morgan Stanley
Subscribe for More Information
07:56 EDTJCPJ.C. Penney downgraded at Craig-Hallum
Subscribe for More Information
07:43 EDTJCPJ.C. Penney downgraded to Sell from Hold at Craig-Hallum
07:22 EDTVRTXCystic Fibrosis Foundation to hold a conference
Subscribe for More Information
06:56 EDTJCPJ.C. Penney pullback a buying opportunity, says Piper Jaffray
Piper Jaffray views yesterday's pullback in shares of J.C. Penney as a buying opportunity, saying the company's turnaround "is very much underway." Piper notes that despite saying Q3 comps are tracking low-single-digits versus prior guidance of mid-single-digits, J.C. Penney management reiterated full-year guidance. The firm reiterates an Overweight rating on Penny with a $13 price target following yesterday's analyst day.
October 8, 2014
16:01 EDTPBROptions Update; October 8, 2014
iPath S&P 500 VIX Short-Term Futures down 2.73 to 29.51. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX PBR AA CLF GILD according to Track Data.
14:26 EDTPBRPetrobras volatility elevated on crude trends lower
Subscribe for More Information
13:43 EDTJCPDepartment stores fall after J.C. Penney cuts view due to difficult environment
Subscribe for More Information
12:25 EDTJCPOn The Fly: Midday Wrap
Subscribe for More Information
12:04 EDTJCPJ.C. Penney now sees Q3 SSS in low single digit range
Subscribe for More Information
12:04 EDTJCPJ.C. Penney announces growth initiatves for 2015-2017
At its 2014 analyst meeting in New York City today, J. C. Penney Company presented its plans for restoring sustainable profitable growth at the Company over the next three years."JCPenney is in a far stronger position today than it was when we began our turnaround effort 18 months ago. While we recognize that there's more work to be done in a highly competitive retail environment, I couldn't be more encouraged by the significant progress our teams have made in such a short amount of time," said Myron E. Ullman, III, CEO. "I am confident that the initiatives we are putting in place will fuel new growth and earn greater customer loyalty as we pursue our vision to become the preferred shopping choice for Middle America." The Company is focused on attracting a new and younger customer by investing in popular in-store attractions that can only be found at JCPenney. To that end, the Company announced the expansion of its highly successful partnership with Sephora, as the companies have agreed to open additional Sephora inside JCPenney locations through 2017, entering new and smaller markets as the first major beauty destination in town. The Company also provided financial performance goals that include achieving $1.2 billion in EBITDA in 2017. This reflects expectations for top line improvements associated with incremental growth potential, as well as continued market share gains in its underlying business, which represents a $3.5B sales opportunity. Of that amount, the Company conservatively expects to realize approximately $2B in incremental sales over the next three years, resulting in mid-single digit sales growth during that period.
11:41 EDTJCPJ.C. Penney says store base count 'roughly' where it needs to be
Says evaluating stores to see if EBITDA accretive. Says "disciplined" regarding promotions. Says won't risk margin over promotions. Says Apple (AAPL), Samsung (SSNLF), Amazon (AMZN) taking "chunk" out of consumer spending. Sees returning to 37%-39% gross margins over time.
11:34 EDTCATCaterpillar maintains dividend of 70c per share
Subscribe for More Information
11:10 EDTJCPOptions with increasing implied volatility
Subscribe for More Information
11:10 EDTJCPJ.C. Penney says succession planning remains 'top priority'
Sees SG&A dollars "roughly flat" over next three years. Sees CapEx averaging $250M-$300M per year.
11:06 EDTJCPJ.C. Penney says expects to be free cash flow positive in FY14
Subscribe for More Information
11:05 EDTJCPJ.C. Penney falls 6%, halted for circuit-breaker after providing guidance
Subscribe for More Information
11:03 EDTJCPJ.C. Penney now sees Q3 SSS up low single digits vs. previous guidance
Subscribe for More Information
11:01 EDTJCPJ.C. Penney says has seen slow down in sales in September
Subscribe for More Information
11:00 EDTJCPJ.C. Penney reaffirms all FY guidance metrics
Subscribe for More Information
10:59 EDTJCPJ.C. Penney sees $14.5B in total sales by 2017
CFO Ed Record says focused on restoring profitability. Says since 4Q13, has had three straight quarters of sales growth. Sees opportunities to improve SG&A and gross margin. Sees $3.5B sales growth opportunity over next three years: Sees continued share growth a $1M opportunity over three years, center core a $1M opportunity, home store a $750M opportunity, omnichannel a $800M opportunity. Sees $1.2B EBITDA growth opportunity over next three years. Sees sales growth in mid single digits through 2017. Free cash flow over next three years "at least" $600M. Comments made at J.C. Penney's Analyst Day.
10:33 EDTJCPJ.C. Penney says seeing "significant" shift to mobile
Subscribe for More Information
10:25 EDTJCPJ.C. Penney says home is $750M growth opportunity
Subscribe for More Information
09:38 EDTPBRActive equity options trading on open
Subscribe for More Information
09:20 EDTJCPJ.C. Penney says will expand Disney stops in stores to 680 from 500
09:20 EDTJCPJ.C. Penney CEOsays will open more Sephora shops in store
Subscribe for More Information
09:20 EDTJCPOn The Fly: Pre-market Movers
Subscribe for More Information
08:18 EDTJCPJ.C. Penney CEO Ullman says customers remain cautious
Subscribe for More Information
08:03 EDTBMYBristol-Myers resolves outstanding U.S. litigation on efavirenz
Bristol-Myers Squibb Company says it has "successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva -- efavirenz -- and Atripla products. Accordingly, we believe that loss of exclusivity in the U.S. for efavirenz should not occur until December 2017. Bristol-Myers Squibb remains committed to delivering our medicines and to developing new and innovative treatments to help patients prevail over serious disease. Atripla is currently the #1 prescribed U.S. regimen in its category, with over 8 million prescriptions written since its launch in 2006. Earlier this year the company submitted a new drug application to the U.S. Food and Drug Administration for a fixed-dose combination of atazanavir sulfate and cobicistat, an investigational pharmacokinetic enhancer. In addition, studies are ongoing for new treatments including an HIV-1 attachment inhibitor, an HIV-1 maturation inhibitor and an anti-PD-L1. The establishment of intellectual property rights allows Bristol-Myers Squibb to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We will continue to defend our intellectual property rights against infringement as we remain focused on providing a deep and broad portfolio of innovative medicines to patients around the world."
07:18 EDTBMYInfectious Diseases Society of America to hold a conference
ID Week 2014 is being held in Philadelphia on October 8-12.
October 7, 2014
16:00 EDTPBROptions Update; October 7, 2014
iPath S&P 500 VIX Short-Term Futures up 2.16 to 32.24 Option volume leaders: AAPL TSLA TWTR AMZN FB VZ AA HTZ NFLX PBR according to Track Data.
13:04 EDTJCPJ.C. Penney to host analyst day
Subscribe for More Information
12:57 EDTJNJJohnson & Johnson October volatility increases into Q3 and outlook
Subscribe for More Information
10:13 EDTJCPJ.C. Penney volatility increases into company hosted analyst day
J.C. Penney October weekly call option implied volatility is at 118, October is at 72, November is at 57, January is at 55, February is at 53; compared to its 26-week average of 54 according to Track Data suggesting large near term price movement into a company hosted analyst day event on October 8.
09:36 EDTPBRActive equity options trading on open
Subscribe for More Information
08:34 EDTBMYBristol-Myers withdrawing NDA for asunaprevir
Given the rapidly evolving hepatitis C treatment landscape in the U.S., Bristol-Myers Squibb has decided that it will not pursue U.S. Food and Drug Administration approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has therefore withdrawn its new drug application for asunaprevir, an NS3/4A protease inhibitor. The company will continue to pursue FDA approval of daclatasvir, a potent, pan-genotypic NS5A complex inhibitor, which is currently being investigated globally in multiple treatment regimens for HCV patients with high unmet need. Bristol-Myers says "The dual regimen was developed to meet the distinct need of the Japanese patient population, and we believe this treatment has the potential to play a major role in curing HCV patients in Japan, as well as in other markets where the HCV patient population is similar to Japan. In the EU, daclatasvir was recently approved for use in combination with other medicinal products across genotypes 1, 2, 3 and 4 for the treatment of HCV infection in adults. Similarly, we believe that daclatasvir-based regimens have the potential to fill continued unmet medical need in the U.S. and elsewhere in the world. We plan to submit additional data for daclatasvir to the FDA from our ongoing clinical trial program focused on difficult-to-treat patients, including patients with HCV genotype 3, patients who are pre- and post-liver transplant, and patients co-infected with HIV. Next month at the annual meeting of The American Association for the Study of Liver Diseases, we will present new data from several daclatasvir-based regimens. We look forward to bringing daclatasvir to patients in the U.S. and will continue to work closely with the FDA to advance our regulatory application, with the aim of bringing the investigational product to market as quickly as possible."
08:33 EDTBMYBristol-Myers withdrawing NDA for asunaprevir
Subscribe for More Information
07:46 EDTVRTXPTC Therapeutics weakness a buying opportunity, says Oppenheimer
Oppenheimer believes that the Street is underestimating the opportunity for PTC Therapeutics' (PTCT) Translarna in the most severe patients with Cystic fibrosis. The firm thinks the drug is not competitive with, and can potentially be complemented by, therapies from Vertex (VRTX). Oppenheimer views the weakness in PTC as a buying opportunity and keeps its Outperform rating on the shares.
07:24 EDTJNJAlliance for Regenerative Medicine
Subscribe for More Information
06:08 EDTJNJJohnson & Johnson Remicade competition could come in 2016, says Wells Fargo
Subscribe for More Information
October 6, 2014
16:00 EDTPBROptions Update; October 6, 2014
iPath S&P 500 VIX Short-Term Futures up 46c to 30.08. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX HPQ C RSH CLF PBR according to Track Data.
10:32 EDTPBRPetrobras spikes higher following Brazilian election results
Subscribe for More Information
09:37 EDTPBRActive equity options trading on open
Subscribe for More Information
09:35 EDTPBRPetrobras upgraded to Buy from Neutral at UBS
Subscribe for More Information
08:04 EDTBMYBristol-Myers announces Opdivo clinical trial with Novartis therapies
Subscribe for More Information
08:02 EDTBMYBristol-Myers announces research collaboration to evaluate Opdivo
Subscribe for More Information
05:14 EDTBMYNovartis announce clinical collaboration with Bristol-Myers
Novartis (NVS) announced that it has entered into a clinical collaboration with Bristol-Myers Squibb (BMY) to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb's investigational PD-1 immune checkpoint inhibitor, Opdivo, in Phase I/II trials of patients with non-small cell lung cancer, or NSCLC. Both studies will be conducted by Novartis. One trial will evaluate the combination of Opdivo with Zykadia, an FDA-approved treatment for patients with anaplastic lymphoma kinase-positive metastatic NSCLC who have progressed on or are intolerant to crizotinib. A second study will investigate Opdivo with INC280, a potent and highly selective inhibitor of c-MET receptor tyrosine kinase, and separately with EGF816, a potent, third-generation EGFR tyrosine kinase inhibitor that is active against T790 mutations. INC280 and EGF816 are currently being investigated in various Phase I/II NSCLC trials. Additional details of the collaboration were not disclosed.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use